Adobe

ByElaine Chen

Sept. 15, 2026

National Biotech Reporter

Elaine Chen

[email protected]

Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writesThe Readout newsletter, and co-hosts STAT’s weekly biotech podcast,The Readout Loud. You can reach Elaine on Signal at elaineywchen.70.

Want to stay on top of the science and politics driving biotech today?Sign upto get our biotech newsletter in your inbox.

Good morning. I was devastated to find out thatwe’ll no longerget sunsets after 7 p.m. until next spring.

Advertisement

The need-to-know this morning

  • Legend BiotechappointedIngrid Zhang as its new CEO. Zhang is a former Novartis executive. She replaces Ying Huang, who resigned in July.

With strong data, Vera to seek full approval of kidney drug

Vera said this morning that its recently launched drug stabilized kidney function and reduced the risk of kidney-related death and other complications in a two-year trial of people with a chronic autoimmune kidney disease.

STAT+ Exclusive Story

Already have an account?Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account?Log in

Monthly

$39

Totals $468 per year

$39/monthGet Started

Totals $468 per year

Starter

$30

for 3 months, then $399/year

$30 for 3 monthsGet Started

Then $399/year

Annual

$399

Save 15%

$399/yearGet Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A QuoteRequest A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/yearGet Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

SubscribeLog Inbiotechnology

,

drug development

,

Drug prices

,

researchSubmit a correction requestReprints

  1. Elaine Chen

    National Biotech Reporter

    Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writesThe Readout newsletter, and co-hosts STAT’s weekly biotech podcast,The Readout Loud. You can reach Elaine on Signal at elaineywchen.70.

Newsletter

Your morning rundown of the science, politics, and money driving biotech today